Abstract
Three major cytokines, namely, tumor necrosis factor (TNF-α), interleukin (IL)-1, and IL-6 are produced by cultured brain cells after various stimuli such as ischemia. Neurones, astrocytes, microglia and oligodendrocytes can produce inflammatory mediators, and cytokine receptors are expressed constitutionally throughout the Central Nervous System (CNS), albeit at low levels. Cytokines are involved in virtually every facet of stroke and they have numerous proinflammatory and pro-coagulant effects on endothelium. TNF-α expression after stroke stimulates expression of tissue factor and adhesion molecules for leukocytes, release of interleukin-1 (IL-1), nitric oxide, factor VIII/von Willebrand factor, platelet-activating factor and endothelin, suppression of the thrombomodulin-protein C-protein S system, reduction of tissue-plasminogen activator and release of plasminogen activator inhibitor-1. Research into the actions of IL-1β in the brain initially focused on its role in host defence responses to systemic disease. IL-1β can also elicit an array of responses which could either inhibit, exacerbate or induce neuronal damage and death. IL-6 can be induced by a variety of molecules including IL-1, TNF-α, transforming growth factor-β and prostaglandins (PGs), and many other mediators such as b-amyloid, interferon-g (IFNg) and IL-4 can potentiate these primary inducers, highlighting the complex nature of IL-6 modulation. Several studies reported that plasma levels of TNF-α and IL-6 are associated with prognosis after ischemic stroke and our group showed that plasma levels of cytokines such as TNF-α, IL-1β are different in every diagnostic subtype of ischemic stroke, and how plasma levels of some immunoinflammatory markers and thrombotic-phybrinolitic markers are predictive of acute ischemic stroke diagnosis in the acute setting.
Keywords: Ischemic Stroke, cytokines, tumor necrosis factor (TNF-α), Neurones, astrocytes, oligodendrocytes, Central Nervous System (CNS)
Current Pharmaceutical Design
Title: Inflammatory Cytokines in Acute Ischemic Stroke
Volume: 14 Issue: 33
Author(s): Antonino Tuttolomondo, Domenico Di Raimondo, Riccardo di Sciacca, Antonio Pinto and Giuseppe Licata
Affiliation:
Keywords: Ischemic Stroke, cytokines, tumor necrosis factor (TNF-α), Neurones, astrocytes, oligodendrocytes, Central Nervous System (CNS)
Abstract: Three major cytokines, namely, tumor necrosis factor (TNF-α), interleukin (IL)-1, and IL-6 are produced by cultured brain cells after various stimuli such as ischemia. Neurones, astrocytes, microglia and oligodendrocytes can produce inflammatory mediators, and cytokine receptors are expressed constitutionally throughout the Central Nervous System (CNS), albeit at low levels. Cytokines are involved in virtually every facet of stroke and they have numerous proinflammatory and pro-coagulant effects on endothelium. TNF-α expression after stroke stimulates expression of tissue factor and adhesion molecules for leukocytes, release of interleukin-1 (IL-1), nitric oxide, factor VIII/von Willebrand factor, platelet-activating factor and endothelin, suppression of the thrombomodulin-protein C-protein S system, reduction of tissue-plasminogen activator and release of plasminogen activator inhibitor-1. Research into the actions of IL-1β in the brain initially focused on its role in host defence responses to systemic disease. IL-1β can also elicit an array of responses which could either inhibit, exacerbate or induce neuronal damage and death. IL-6 can be induced by a variety of molecules including IL-1, TNF-α, transforming growth factor-β and prostaglandins (PGs), and many other mediators such as b-amyloid, interferon-g (IFNg) and IL-4 can potentiate these primary inducers, highlighting the complex nature of IL-6 modulation. Several studies reported that plasma levels of TNF-α and IL-6 are associated with prognosis after ischemic stroke and our group showed that plasma levels of cytokines such as TNF-α, IL-1β are different in every diagnostic subtype of ischemic stroke, and how plasma levels of some immunoinflammatory markers and thrombotic-phybrinolitic markers are predictive of acute ischemic stroke diagnosis in the acute setting.
Export Options
About this article
Cite this article as:
Tuttolomondo Antonino, Di Raimondo Domenico, di Sciacca Riccardo, Pinto Antonio and Licata Giuseppe, Inflammatory Cytokines in Acute Ischemic Stroke, Current Pharmaceutical Design 2008; 14 (33) . https://dx.doi.org/10.2174/138161208786848739
DOI https://dx.doi.org/10.2174/138161208786848739 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Burkholderia mallei and Burkholderia pseudomallei: The Causative Micro-organisms of Glanders and Melioidosis
Recent Patents on Anti-Infective Drug Discovery Astatine Radiopharmaceuticals: Prospects and Problems
Current Radiopharmaceuticals Research Progress in Live Attenuated Brucella Vaccine Development
Current Pharmaceutical Biotechnology Brain Endothelial Cell-Cell Junctions: How to “Open” the Blood Brain Barrier
Current Neuropharmacology Editorial [Revisiting the Paris Declaration: Pharmacogenomics and Personalized Medicine as Accelerators for Development Aid and Effectiveness]
Current Pharmacogenomics and Personalized Medicine Clinical Pharmacology of Current and Future Drugs for the Acute Treatment of Migraine: A Review and An Update
Current Clinical Pharmacology Health Care Providers’ Need for Child and Adolescent Mental Health (CAMH) Training in South Western Nigeria
Adolescent Psychiatry Serial Extraction Technique of Rich Antibacterial Compounds in <i>Sargassum cristaefolium</i> Using Different Solvents and Testing their Activity
Current Bioactive Compounds Targeted Multimodal Liposomes for Nano-delivery and Imaging: An Avenger for Drug Resistance and Cancer
Current Gene Therapy High Throughput Screen Identifies Natural Product Inhibitor of Phenylalanyl-tRNA Synthetase from Pseudomonas aeruginosa and Streptococcus pneumoniae
Current Drug Discovery Technologies Kainic Acid-Induced Neurotoxicity: Targeting Glial Responses and Glia-Derived Cytokines
Current Neuropharmacology Estrogen Receptor Beta in Cancer: an Attractive Target for Therapy
Current Pharmaceutical Design Mass Balance Study of the Engineered Cationic Antimicrobial Peptide, WLBU2, Following a Single Intravenous Dose of 14C-WLBU2 in Mice
Current Reviews in Clinical and Experimental Pharmacology Editorial
Current Medical Imaging Caspase-3 Short Hairpin RNAs: A Potential Therapeutic Agent in Neurodegeneration of Aluminum-Exposed Animal Model
Current Alzheimer Research Brain-metastatic Breast Cancer: Clinical Considerations and Pharmacological Approaches
Anti-Cancer Agents in Medicinal Chemistry The Current WHO Classification of Tumours of the Central Nervous System: Histopathology and Additional Diagnostic Methods
Current Medical Imaging Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry GH-Inhibitory Activity of Novel Somatostatin Agonists: Potential Applications in Acromegaly
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Advances in Neuroimaging for HIV-1 Associated Neurological Dysfunction: Clues to the Diagnosis, Pathogenesis and Therapeutic Monitoring
Current HIV Research